Sees FY26 revenue to represent approximately 20%-22% vs. last year. Sees FY26 adjusted EBITDA between (29M)-(32M).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- SOPHiA GENETICS Posts Strong 2025 Growth and Reaffirms 2026 Outlook
- SOPH Upcoming Earnings Report: What to Expect?
- Sophia Genetics signs two major U.S. healthcare systems
- SOPHiA GENETICS Expands Perceptive Credit Facility With New $25 Million Term Loan Capacity and Additional Warrants
- Sophia Genetics price target raised to $7 from $6 at Guggenheim